{"id":"artesunate-and-pyronaridine","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Artesunate, a semi-synthetic artemisinin derivative, generates free radicals that damage parasite proteins and membranes. Pyronaridine is an arylmethanol antimalarial that inhibits parasite heme polymerization and disrupts mitochondrial function. Together, they provide rapid parasite clearance and reduce the risk of resistance development through complementary mechanisms of action.","oneSentence":"Artesunate and pyronaridine are antimalarial agents that work synergistically to kill malaria parasites by generating reactive oxygen species and disrupting parasite metabolism.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:18:37.868Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Uncomplicated malaria caused by Plasmodium falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi"}]},"trialDetails":[{"nctId":"NCT07060794","phase":"PHASE4","title":"Tafenoquine and ACTs (TADORE- Plus)","status":"NOT_YET_RECRUITING","sponsor":"Menzies School of Health Research","startDate":"2026-06","conditions":"Vivax Malaria","enrollment":507},{"nctId":"NCT07470424","phase":"PHASE1","title":"A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults","status":"NOT_YET_RECRUITING","sponsor":"University of Oxford","startDate":"2026-06-01","conditions":"Malaria","enrollment":24},{"nctId":"NCT07362498","phase":"","title":"Health Systems Implementation and Molecular Surveillance of Multiple First-Line Treatments for Uncomplicated Malaria in Western Kenya","status":"COMPLETED","sponsor":"Strathmore University","startDate":"2020-06-01","conditions":"Malaria Falciparum","enrollment":316},{"nctId":"NCT06962319","phase":"PHASE3","title":"Safety of Antimalarials in the FIRst trimEster","status":"RECRUITING","sponsor":"Liverpool School of Tropical Medicine","startDate":"2025-09-30","conditions":"Malaria, Pregnancy, Malaria, Antepartum, Malaria (Uncomplicated)","enrollment":1510},{"nctId":"NCT05343312","phase":"PHASE4","title":"In Vivo Efficacy of Artemether-Lumefantrine, Amodiaquine-Artesunate, Dihydroartemisinin-Piperaquine, and Pironaridine-Artesunate in Mozambique","status":"COMPLETED","sponsor":"Centro de Investigacao em Saude de Manhica","startDate":"2022-03-16","conditions":"Malaria","enrollment":870},{"nctId":"NCT04532931","phase":"PHASE2","title":"Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2020-09-03","conditions":"COVID-19","enrollment":192},{"nctId":"NCT05441410","phase":"PHASE1, PHASE2","title":"Comparing Safety and Protective Efficacy of Vaccine Candidate PfSPZ-CVac and MVA ME-TRAP/ ChAd63 ME-TRAP in Adults","status":"NOT_YET_RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2025-06-01","conditions":"Malaria","enrollment":30},{"nctId":"NCT04695197","phase":"PHASE3","title":"Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso","status":"COMPLETED","sponsor":"Liverpool School of Tropical Medicine","startDate":"2021-01-08","conditions":"Covid-19, Malaria","enrollment":143},{"nctId":"NCT01868438","phase":"PHASE1","title":"Relative Bioavailability of Pyronaridine-artesunate in Tablet and Granule Formulations in Healthy Volunteers","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2013-05","conditions":"Malaria","enrollment":60},{"nctId":"NCT01523002","phase":"PHASE1","title":"Drug Interaction Study of Pyronaridine-artesunate & Metoprolol, & Redosing Study of Pyronaridine-artesunate","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2012-01","conditions":"Malaria","enrollment":56},{"nctId":"NCT05929157","phase":"PHASE1, PHASE2","title":"A Crossover Bioavailability Clinical Trial of Parenteral Pyronaridine and Artesunate","status":"UNKNOWN","sponsor":"Centre de Recherche Médicale de Lambaréné","startDate":"2023-09-01","conditions":"Severe Malarial Treatment","enrollment":12},{"nctId":"NCT05084911","phase":"PHASE3","title":"The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients (Phase3)","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2021-10-18","conditions":"COVID-19","enrollment":1807},{"nctId":"NCT00682630","phase":"PHASE1","title":"Bioequivalence Trial of Pyronaridine Artesunate To-be-marketed Tablet to the Clinical Trial Reference Tablet","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2007-09","conditions":"Malaria","enrollment":42},{"nctId":"NCT01156389","phase":"PHASE1","title":"Pyronaridine Artesunate-Ritonavir Drug-drug Interaction Study","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2010-07","conditions":"Malaria","enrollment":34},{"nctId":"NCT05633420","phase":"PHASE2","title":"Pilot Clinical Trial to Explore Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2022-07-24","conditions":"COVID-19","enrollment":20},{"nctId":"NCT04783051","phase":"PHASE3","title":"Comparison of ISTp- PYRAMAX-US-RDT to IPTp-SP to Prevent Malaria in Pregnant Women in DRC (ULTRAPYRAPREG)","status":"COMPLETED","sponsor":"University of Kinshasa","startDate":"2021-05-06","conditions":"Malaria in Pregnancy","enrollment":250},{"nctId":"NCT00331136","phase":"PHASE2","title":"Pyronaridine and Artesunate (3:1) in Children With Acute Uncomplicated Plasmodium Falciparum Malaria","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2006-06","conditions":"Uncomplicated Plasmodium Falciparum Malaria","enrollment":60},{"nctId":"NCT05192265","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-Lumefantrine","status":"COMPLETED","sponsor":"University of Ibadan","startDate":"2019-05-20","conditions":"Malaria Fever, Plasmodium Falciparum Malaria, Uncomplicated Malaria","enrollment":172},{"nctId":"NCT05052502","phase":"NA","title":"Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand","status":"UNKNOWN","sponsor":"University of California, San Francisco","startDate":"2020-11-01","conditions":"Plasmodium Falciparum Malaria, Plasmodium Vivax Malaria","enrollment":49118},{"nctId":"NCT04265573","phase":"","title":"Feasibility, Acceptability and Costs of a Multiple First-lines Artemisinin-based Combination Therapies","status":"COMPLETED","sponsor":"Groupe de Recherche Action en Sante","startDate":"2018-11-10","conditions":"Malaria","enrollment":150000},{"nctId":"NCT04368910","phase":"PHASE3","title":"Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria","status":"TERMINATED","sponsor":"Medicines for Malaria Venture","startDate":"2007-09-06","conditions":"Malaria","enrollment":30},{"nctId":"NCT00541385","phase":"PHASE3","title":"Pyronaridine Artesunate 3:1 Granule Formulation vs. Coartem© Crushed Tablets in P. Falciparum Malaria Pediatric Patients","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2007-10","conditions":"Malaria","enrollment":535},{"nctId":"NCT00440999","phase":"PHASE3","title":"Pyronaridine Artesunate (3:1) in Children and Adults With Acute Plasmodium Vivax Malaria","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2007-03","conditions":"Malaria","enrollment":456},{"nctId":"NCT00422084","phase":"PHASE3","title":"Pyronaridine Artesunate (3:1) Versus Coartem® in P Falciparum Malaria Patients","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2007-01","conditions":"Malaria","enrollment":1272},{"nctId":"NCT01594931","phase":"PHASE2","title":"Phase II Dose-ranging Study of Pyronaridine/Artesunate in Adults Patients With Plasmodium Falciparum Malaria","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2005-07","conditions":"Plasmodium Falciparum Malaria","enrollment":477},{"nctId":"NCT00403260","phase":"PHASE3","title":"Pyronaridine - Artesunate (3:1) Versus Mefloquine Plus Artesunate in Plasmodium Falciparum Malaria Patients","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2007-01","conditions":"Falciparum Malaria","enrollment":1271},{"nctId":"NCT04701606","phase":"PHASE2, PHASE3","title":"The Safety and Efficacy of Pyronaridine-artesunate (Pyramax® or Artecom®)in COVID-19 Patients","status":"UNKNOWN","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2021-03-29","conditions":"Covid19","enrollment":402},{"nctId":"NCT04475107","phase":"PHASE2","title":"The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2020-07-09","conditions":"COVID-19","enrollment":113},{"nctId":"NCT04778813","phase":"PHASE4","title":"Evaluation of Three Artemisinin-based Combinations for the Treatment of Uncomplicated Malaria in Childreen in Burkina Faso (CHIMIO2)","status":"UNKNOWN","sponsor":"Centre national de recherche et de formation sur le paludisme","startDate":"2021-06-01","conditions":"Malaria, Burkina Faso","enrollment":1050},{"nctId":"NCT03726593","phase":"PHASE4","title":"Drug Combinations of Atovaquone-Proguanil (AP) With ACT","status":"UNKNOWN","sponsor":"Armed Forces Research Institute of Medical Sciences, Thailand","startDate":"2018-10-04","conditions":"Plasmodium Falciparum Malaria (Drug Resistant)","enrollment":252},{"nctId":"NCT04264130","phase":"PHASE2","title":"Effect of Artemisinin-based Combination Therapies on Schistosomiasis on Malaria Co-infection","status":"COMPLETED","sponsor":"Centre de Recherche Médicale de Lambaréné","startDate":"2018-07-31","conditions":"Schistosomiasis Haematobia","enrollment":54},{"nctId":"NCT04049916","phase":"PHASE2, PHASE3","title":"Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum Transmission","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2019-09-12","conditions":"Malaria,Falciparum","enrollment":100},{"nctId":"NCT03814616","phase":"PHASE2","title":"Pyramax in Asymptomatic Carriers of P. Falciparum Monoinfections","status":"UNKNOWN","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2018-10-03","conditions":"Malaria,Falciparum","enrollment":300},{"nctId":"NCT03201770","phase":"PHASE4","title":"Cohort Event Monitoring Study of Pyramax®","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2017-06-22","conditions":"Malaria,Falciparum","enrollment":8572},{"nctId":"NCT02389439","phase":"PHASE2","title":"Efficacy and Safety of Pyronaridine-artesunate for the Treatment in Uncomplicated Falciparum Malaria","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-03-01","conditions":"Malaria, Falciparum","enrollment":123},{"nctId":"NCT02411994","phase":"PHASE3","title":"Pyronaridine-artesunate and Artemether-lumefantrine for the Treatment of Paediatric Malaria","status":"COMPLETED","sponsor":"Royal Tropical Institute","startDate":"2015-10","conditions":"Malaria","enrollment":197},{"nctId":"NCT01552330","phase":"PHASE1","title":"Pharmacokinetic Study of Primaquine and Pyronaridine-Artesunate in Healthy Subjects","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2012-05","conditions":"Healthy","enrollment":17}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Artesunate and Pyronaridine","genericName":"Artesunate and Pyronaridine","companyName":"Armed Forces Research Institute of Medical Sciences, Thailand","companyId":"armed-forces-research-institute-of-medical-sciences-thailand","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Artesunate and pyronaridine are antimalarial agents that work synergistically to kill malaria parasites by generating reactive oxygen species and disrupting parasite metabolism. Used for Uncomplicated malaria caused by Plasmodium falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}